A Randomized, Double-Blind, Placebo Controlled , Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI Following Cardiac Surgery

Trial Profile

A Randomized, Double-Blind, Placebo Controlled , Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI Following Cardiac Surgery

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Teprasiran (Primary)
  • Indications Acute kidney injury
  • Focus Therapeutic Use
  • Sponsors Quark Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2017 According to a Quark Pharmaceuticals media release, data will be presented at the EuroTIDES conference 2017.
    • 04 Nov 2017 Results presented in a Quark Pharmaceuticals Media Release.
    • 04 Nov 2017 According to a Quark Pharmaceuticals media release, data were presented at the American Society of Nephrology (ASN) / Kidney Week.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top